Nasal septum perforation and bevacizumab Journal Article
| Authors: | Power, D. G.; Kemeny, N. E. |
| Article Title: | Nasal septum perforation and bevacizumab |
| Abstract: | The use of targeted/biologic therapies is now commonplace in the treatment of malignant and non-malignant diseases. The novel mode of action of these drugs has resulted in unpredictable and in some cases unexpected side effects. Given the widespread use of bevacizumab and its distinct mode of action, it is important that oncologists report any unexpected adverse events that may be associated with the drug. Herein, we report three cases of spontaneous nasal septum perforation secondary to bevacizumab. We hypothesize an etiology for this rare event and reasons why it is reasonable to rechallenge the patient. © 2010 Springer Science+Business Media, LLC. |
| Keywords: | adult; aged; cancer surgery; anamnesis; cancer recurrence; case report; bevacizumab; fluorouracil; cancer combination chemotherapy; drug withdrawal; hypertension; capecitabine; colorectal cancer; ovarian cancer; computer assisted tomography; breast cancer; dexamethasone; cetuximab; irinotecan; panitumumab; colorectal carcinoma; liver metastasis; lung metastasis; colonoscopy; folinic acid; targeted therapy; drug substitution; oxaliplatin; drug treatment failure; floxuridine; epistaxis; colon adenocarcinoma; hyperlipidemia; abdominal discomfort; nasal septum perforation; abnormal feces composition; nose congestion; nose septum perforation |
| Journal Title: | Medical Oncology |
| Volume: | 28 |
| Issue: | 1 |
| ISSN: | 1357-0560 |
| Publisher: | Humana Press Inc |
| Date Published: | 2011-03-01 |
| Start Page: | 89 |
| End Page: | 93 |
| Language: | English |
| DOI: | 10.1007/s12032-010-9464-9 |
| PROVIDER: | scopus |
| PUBMED: | 20213219 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 23 June 2011" - "CODEN: MONCE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work